October 2025 NASDAQ: AVR | ASX: AVR Disclaimer This presentation has been prepared by Anteris Technologies Global Corp. ("Anteris," the "Company," "we" or "us" or "our"). This presentation, and its contents and the accom

October 2025 NASDAQ: AVR | ASX: AVR

Disclaimer This presentation has been prepared by Anteris Technologies Global

Corp. ("Anteris," the "Company," "we" or "us" or "our"). This presentation, and its contents and the accompanying discussion with management are confidential and may not be further copied, distributed or passed on, directly or indirectly, to

any other person or published or reproduced directly or indirectly, in whole or in part, by any medium or in any form for any purpose without the Company's prior written consent. The recipient should not construe the contents of this

presentation as legal, tax, accounting, investment advice or recommendation or business, financial or related advice. The recipient should consult its own counsel and tax and financial advisors as to legal and related matters concerning the

matters described in this presentation. This presentation does not purport to be all-inclusive or to contain all of the information that the recipient may require. To the maximum extent permitted by law, none of the Company, its

representatives, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of the information contained in this presentation. Forward-Looking

Statements This presentation (including oral commentary that accompanies this presentation) contains forward-looking statements, including statements related to our business, products and the PARADIGM Trial. Any statements about our

expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and may be forward-looking. In some cases, you can identify forward-looking statements through the use of

words such as "believes," "expects," "may," "will," "should," "would," "seeks," "intends," "plans," "pro forma," "estimates," "contemplates," "aims," "continues," "anticipates" and similar expressions. Although we believe that the expectations

reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, some of which are beyond

our control. Among the factors that could cause actual results to differ materially from those suggested by forward-looking statements are: our current and future research and development activities, including clinical testing and manufacturing

and related costs and timing; sufficiency of our capital resources; our product development and business strategy, including the potential size of the markets for our products and future development and/or expansion of our products in our

markets; our ability to commercialize products and generate product revenues; our ability to raise additional funding when needed; any statements concerning anticipated regulatory activities, including our ability to obtain regulatory

clearances; our research and development expenses; and risks facing our operations and intellectual property; and the other risks described in our Annual Report on Form 10-K for the year ended December 31, 2024 and the other filings we make

with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize or should any of these assumptions prove to be incorrect, our actual future results, performance and events and circumstances may differ

in material respects from the performance projected in these forward-looking statements. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake any obligation to update

any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in the Company's expectations, except as may be required by law. Accordingly, the Company cautions you

not to place any undue reliance on any forward-looking statements. Industry Data This presentation also includes data, forecasts and information obtained from industry publications and other information available to us. Some data is also

based on our good faith estimates, which are derived from management's knowledge of the industry and independent sources. We have not independently verified any of the data from third-party sources, nor have we ascertained the underlying

assumptions relied upon therein. While we are not aware of any misstatements regarding the industry data presented herein, estimates and forecasts involve uncertainties and risks and are subject to change based on various

factors. Milestones This presentation contains various milestones. These milestones are not projections and instead are forward-looking goals that are subject to significant business, economic, regulatory and competitive uncertainties and

contingencies, many of which are beyond the control of the Company and its management and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary, and those variations may be material.

Nothing in this presentation should be regarded as a representation by any person that these milestones will be achieved and the Company undertakes no duty to update these milestones. No Offer or Solicitation This presentation shall not

constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. Before you invest, you

should read the documents we file with the SEC for more complete information about us. You can obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov. 2

Anteris Technologies - Executing on strategy 4 Building commercial readiness

for a new class of TAVR that mimics a healthy aortic valve Successfully priced U.S. IPO and listed on Nasdaq in December 2024 - Enhancing liquidity and visibility in the world's largest healthcare investment market 1 Total of 130 DurAVR

THV patients, 49 patients treated YTD- Building momentum, 38% of all patients enrolled in 6 months (Jan-Jun 2025) 2 Data showcased by global KOLs at leading cardiovascular conferences- CRT (Mar), Sydney Valves (Mar), Euro PCR (May), CSI

Frankfurt (Jun), New York Valves (Jun) 3 First-in-human DUAL valve-in-valve success with DurAVR THV- DurAVR successfully implanted in both aortic (Mar) and mitral ViV procedures (May) 4 Hosted global investigator meeting to launch

pivotal PARADIGM Trial- Setting the foundation for accelerated site activation and patient enrollment (Jun) 5

Investment Highlights 5 The only biomimetic balloon expandable TAVR with

130 treated patients Path to Commercialization Poised to disrupt a high value, growth market DurAVR THV is the only balloon expandable aortic valve to deliver curative, pre-disease hemodynamics1,2. Forecasted US$9.9bn by 2028 (US12.5bn

with Valve-in-Valve)3. Underpenetrated with 80-85% of severe aortic stenosis patients untreated4. 130 patients. Strong performance at 30 days & 1 year. PARADIGM Pivotal trial targeted 4Q25*, 50% DurAVR vs. 50% SAPIEN or Evolut.

Potential pathway to FDA & CE Mark approval. Scaled manufacturing, engaged global KOLs, early adopter site identification. Compact market allows a capital-efficient launch with lean, scalable field force. Established TAVR reimbursement

pathways. Proprietary, First-in-Class TAVR Multi-billion-dollar global TAVR market Clinical Validation Commercial Readiness Commercial Launch Garg, P., Markl, M., Sathananthan, J. et al. Restoration of flow in the aorta: a novel

therapeutic target in aortic valve intervention. Nat Rev Cardiol 21, 264-273 (2024). https://doi.org/10.1038/s41569-023-00943-6. Garg, P. DurAVR TAVI: biomimetic design restores flow and leads to significant LV mass regression. MRI study.

Oral presentation at PCR London Valves; Nov 2024; London, England. Future Market Insights. Transcatheter Heart Valve Replacement (TAVR) Market: Global Industry Analysis 2016 - 2023 and Opportunity Assessment 2024 - 2034. Future Market

Insights; 2024. Available from: https://www.futuremarketinsights.com/reports/transcatheter-heart-valve-replacement-tavi-market Gahl B, elik M, Head SJ, et al. Natural History of Asymptomatic Severe Aortic Stenosis and the Association of

Early Intervention With Outcomes: A Systematic Review and Meta-analysis. JAMA Cardiol. 2020;5(10):1102-1112. doi:10.1001/jamacardio.2020.2497. *Subject to regulatory approval

Highly Experienced Leadership - Clinical, Operational, Commercial 6 Mr.

McDonnell has served as CFO since November 2018. Prior to his appointment he worked at KPMG for over 24 years, where Mr. McDonnell held several senior positions including 10 years as a partner. He has experience in restructurings, acquisitions,

divestments, privatizations and other significant financial transactions. Matthew McDonnell Chief financial officer Dr. Meduri has served as Anteris' CMO since August 2021. Dr. Meduri is a practicing Interventional Cardiologist at Stern

Cardiovascular Foundation, Memphis, TN and a recognized global leader in the field of valvular heart disease with over 3,500 career structural heart procedures and over 300 annually. He has served as global head of many TAVR, mitral and

tricuspid trials. Dr. Chris Meduri Chief medical officer Mr. Paterson has served as CEO since March 2017 and was appointed Vice Chairman in March 2025. He held global positions in big pharma incl. Merck KGaA ("Merck") from 2005-2013, and

Roche (1995-2005). His roles included Global Head of CV Medicine, President of Europe, Israel, Canada & Australia, President of Emerging Markets incl. Russia & LATAM, CEO of Japan, Head of Commercial Operations in China, Head of Korea,

and Product Manager. He also sat on a NASDAQ board (CHPD) and led a $5B sale of that business. He has launched global healthcare products 36 times totaling billions in revenue and driven dozens of acquisitions, in-licensing and out-licensing

deals globally. Wayne Paterson VICE CHAIRMAN & CEO Mr. St Denis has served as COO since July 2017 and was appointed President and Director in March 2025. From 2008-2017 he held senior positions at Merck including Head of Commercial

Operations for Europe and Canada, and Head of Operations for Emerging Markets. From 1996-2006, he held senior roles at Millennium Pharmaceuticals Inc. David St Denis President & Director

Board of Directors 7 John Seaberg Chairman Mr. Seaberg has been Chairman since

March 2017 and a director since October 2014. He has served as Board Chair of Preceptis Medical Inc since 2016 and Phraxis Medical Inc since 2009. He was Executive VP at Cedar Point Capital from 2015-2023. He was Chair of Synovis Inc., a

manufacturer of medical devices and tissue products from 2008-2012. Mr. Paterson has served as CEO since March 2017 and was appointed Vice Chairman in March 2025. He held global positions in big pharma incl. Merck KGaA ("Merck") from

2005-2013, and Roche (1995-2005). His roles included Global Head of CV Medicine, President of Europe, Israel, Canada & Australia, President of Emerging markets incl. Russia & LATAM, CEO of Japan, Head of Commercial Ops in China. He sat

on a NASDAQ board (CHPD) and led a $5B sale of that business. He has launched 36 global healthcare products totaling billions in revenue. Wayne Paterson VICE CHAIRMAN & CEO DIRECTOR & Company secretary Mr. St Denis has served as COO

since July 2017 and was appointed President and Director in March 2025. From 2008-2017 he held senior positions at Merck including Head of Commercial Operations for Europe and Canada, and Head of Operations for Emerging Markets. From 1996-2006,

he held senior roles at Millennium Pharmaceuticals Inc. David St Denis President & Director Greg Moss Non-Executive Director Mr. Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance

Officer of Evommune, Inc. Prior to Evommune, he served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, culminating in Kadmon's $1.9 billion acquisition in 2021. Dave

Roberts Non-Executive Director Mr. Roberts joined LeMaitre Vascular (NASDAQ: LMAT) in 1997 as its twelfth employee and has served as a Board Director since 2001 and as President since 2007. Mr. Roberts has also served as a Board Director of

Lexington Medical since 2023 and of Parasole Restaurant Holdings since 2013. Stephen Denaro Mr. Denaro has been a director and Company Secretary since October 2018. Mr. Denaro serves as director and sole shareholder of Trio Business

Intermediaries Pty Ltd. He has over 25 years of experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance.

Global Manufacturing Footprint 8 Purpose-built infrastructure designed for

efficient scale-up and commercial readiness

TAVR market opportunity expected to reach US$9.9bn in 2028 9 Currently 3

industry trials in progress, anticipated to be completed in 2025 Potential for further significant growth Edwards Lifesciences: SAPIEN 3 platform FDA approved for asymptomatic severe AS patients based on EARLY TAVR Trial (May

2025) Medtronic: to explore the treatment of moderate AS with early TAV implantation (TAVI) before AS becomes severe Edwards Lifesciences: will examine the TAVR procedure in patients who are > 65 years, have moderate AS, and have at least

one additional risk factor Gahl B, elik M, Head SJ, et al. Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes: A Systematic Review and Meta-analysis. JAMA Cardiol.

2020;5(10):1102-1112. doi:10.1001/jamacardio.2020.2497. Future Market Insights. Transcatheter Heart Valve Replacement (TAVR) Market: Global Industry Analysis 2016 - 2023 and Opportunity Assessment 2024 - 2034. Future Market Insights; 2024.

Available from: https://www.futuremarketinsights.com/reports/transcatheter-heart-valve-replacement-tavi-market. Underpenetrated patient population with only 15-20%1 of severe aortic stenosis cases treated today

Aortic Stenosis (AS) - Current Treatment Options 11 A life-threatening

condition caused by narrowing of the aortic valvePatients with severe AS have a 50% risk of dying within 2 Years1 Leon MB, Smith CR, Mack M, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo

Surgery. N Engl J Med. 2010;363(17):1597-1607. doi:10.1056/NEJMoa1008232. SAVR: Surgical aortic valve replacement, TAVR: Transcatheter aortic valve replacement SAVR - Invasive, open-heart surgery TAVR - Minimally invasive procedure

12 Yesterday's TAVRs were not developed for today's patients DurAVR was

deliberately designed for younger and more active patients STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol (2020);76:2492-2516. N Engl J Med 2019; 380:1695-1705. Patients need a safer alternative to open

heart surgery Patients need a valve that restores an active lifestyle for the rest of their life First & second generation TAVRs ~85 yrs Third generation TAVRs ~73 yrs 2011-2013 average patient age was 841 2016-2017 average patient

age is 73 & declining2

Anteris set out to address the needs in TAVR by asking different

questions 13 Our expert panel of physicians advised the Company what they wanted in a next generation valve: Balloon-expandable deliveryDrives clinical adoption - Controlled expansion, predictable placement, commissure alignment Clinically

better For younger and more active patients Curative, pre-disease hemodynamics, laminar flow How can we mimic a native valve? How does a healthy aortic valve perform? How do we deliver the valve? How can we put that valve in a frame?

Single-piece, native-shaped biomimetic design built to mimic the performance of a

healthy aortic valve. DurAVR : A New Class of TAVR 14

DurAVR Sustained hemodynamic performance to 1 year 15 Puri, R. DurAVR : A Novel

First-in-Class Biomimetic Transcatheter Aortic Valve 1-Year Performance. Oral Presentation at: Sydney Valves; March 2025; Sydney, Australia. MPG (Mean Pressure Gradient mmHg) DVI (Doppler Velocity Index) 2.1 EOA (Effective Orifice Area

cm2) 8.6 0.58 Mean Annular Diameter: 22.4 mm Mean Pressure Gradient (MPG) The average pressure across the aortic valve between the left ventricle and aorta Patients with severe AS have MPG 40 mmHg Effective Orifice Area (EOA) The

cross-sectional area of the aortic valve opening that is available for blood flow Patients with severe AS have an EOA of 1cm2 Doppler Velocity Index (DVI) An index that expresses EOA as a proportion of valve area DVI represents the

physical ratio of a patient's aortic valve area to the left ventricular outflow tract area

16 " A balloon expandable valve with self-expanding hemodynamics is like the

holy grail. Dr Michael ReardonProfessor of Cardiothoracic Surgery, Allison Family Distinguished Chair of Cardiovascular Research Methodist DeBakey Heart & Vascular Center " Clinician panel discussion, PCR London Valves 2023.

Restores flow dynamics, significantly reducing left ventricular (LV)

mass 17 SEVERE AORTIC STENOSIS EOA 2.2cm2 MPG 7.5 mmHg IMPAIRED FLOW NORMAL LAMINAR FLOW Waggoner T. DurAVR Biomimetic Transcatheter Heart Valve: Early Feasibility Study (EFS) Update. Oral Presentation at: CRT Conference, March 2024;

Washington, USA. Cavalcante J. Biomimetic Design Restores Flow and Hemodynamics and Leads to Significant LV Mass Regression: update from First-in-Human (FIH) Study with novel DurAVR Transcatheter Heart Valve . Oral Presentation at: New York

Valves; June 2024; New York, New York, USA. A narrowed aortic valve creates increased pressure in the left ventricle. Narrowed EOA(Effective Orifice Area) High MPG(Mean Pressure Gradient) EnlargedLeft Ventricular Thickness NormalLeft

Ventricular Thickness Increased LV mass is an adaptive response to the increased workload caused by the narrowed aortic valve. Untreated it may progress to heart failure. EFS Data1 29% Reduction in LV Mass Index2

Normal Aortic Flow DurAVR is the first aortic valve to restore normal aortic

flow 18 Post DurAVR THV implant Healthy Aortic Valve FD = 14% FRR = 4% (n=5) FD = 46% FRR = 23% When compared to a healthy aortic valve, DurAVR THV showed no significant difference in flow (p>0.05) Severe AS Sapien 3 CEP

Magna Ease Evolut R FD = 10% FRR = 1% (n=5) FD = 48% FRR = 35% FD = 27% FRR = 30% FD = 25% FRR = 4 % FD = Flow Displacement | FRR = Flow Reversal Ratio Garg, P. DurAVR TAVI novel leaflet design restores ascending aortic flow

haemodynamics on cardiac MRI: First-in-human study. Oral presentation at PCR London Valves; November 2022; London, England. Garg, P. DurAVR TAVI: biomimetic design restores flow and leads to significant LV mass regression. MRI study. Oral

presentation at PCR London Valves; November 2024; London, England. Cavalcante, J. Biomimetic Design Restores Flow and Hemodynamics and Leads to Significant LV Mass Regression: update from First-in-Human (FIH) Study with novel DurAVRTM

Transcatheter Heart Valve. Oral presentation at New York Valves; June 2024; New York, New York, USA. Controls with no known aortic valve disease assessed and age-height-weight matched to reduce bias. Limitations: Small sample size. Control

n=5, DurAVR n=5, Other TAVRs n=4, SAVR n=8. Impaired Aortic Flow Normal Valve (n=5) vs: TAVR (n=4) p<0.05 | SAVR (n=8) p<0.01

Existing bioprosthetic valves fail and patients need retreatment ViV